Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Growth in Short Interest

Entera Bio Ltd. (NASDAQ:ENTX) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 95,800 shares, a growth of 102.5% from the December 31st total of 47,300 shares. Based on an average daily volume of 132,000 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Trading of Entera Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Parkman Healthcare Partners LLC raised its stake in Entera Bio by 2.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock worth $781,000 after acquiring an additional 9,558 shares in the last quarter. Perigon Wealth Management LLC purchased a new stake in shares of Entera Bio in the fourth quarter valued at about $325,000. Finally, Signature Estate & Investment Advisors LLC purchased a new stake in shares of Entera Bio in the third quarter valued at about $90,000. Institutional investors and hedge funds own 14.11% of the company’s stock.

Entera Bio Price Performance

NASDAQ:ENTX traded down $0.03 during midday trading on Friday, hitting $2.30. The company’s stock had a trading volume of 15,193 shares, compared to its average volume of 230,089. The firm has a market cap of $82.29 million, a P/E ratio of -8.85 and a beta of 1.49. Entera Bio has a fifty-two week low of $0.68 and a fifty-two week high of $3.35. The firm’s 50 day moving average is $2.17 and its 200-day moving average is $1.91.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Entera Bio in a research note on Monday, November 11th.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.